Senior Medical Science LiaisonInflaRx Pharmaceuticals, Inc.Pittsburgh, Pennsylvania, United States
Disclosure(s): InflaRx Pharmaceuticals, InflaRx GmbH: Employee
85 - Improved Survival with Dual Immunomodulator Treatment of ARDS by blocking C5a and IL-6 Activity: Subanalysis from the PANAMO Study in Critically Ill COVID-19 Patients
Thursday, October 17, 202411:15 AM – 11:30 AM US PT
